<SEC-DOCUMENT>0001477932-22-001739.txt : 20220330
<SEC-HEADER>0001477932-22-001739.hdr.sgml : 20220330
<ACCEPTANCE-DATETIME>20220330161400
ACCESSION NUMBER:		0001477932-22-001739
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220330
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220330
DATE AS OF CHANGE:		20220330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			VOLITIONRX LTD
		CENTRAL INDEX KEY:			0000093314
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				911949078
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36833
		FILM NUMBER:		22786616

	BUSINESS ADDRESS:	
		STREET 1:		13215 BEE CAVE PARKWAY
		STREET 2:		GALLERIA OAKS B, SUITE 125
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78738
		BUSINESS PHONE:		1 (646) 650-1351

	MAIL ADDRESS:	
		STREET 1:		13215 BEE CAVE PARKWAY
		STREET 2:		GALLERIA OAKS B, SUITE 125
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78738

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STANDARD CAPITAL CORP
		DATE OF NAME CHANGE:	19990812
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>vnrx_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:vnrx="http://vnrx.com/20220330"><head><title>vnrx_8k.htm</title><!--Document Created by XBRLMaster--><meta http-equiv="Content-Type" content="text/html" /></head><body style="text-align:left;font:10pt times new roman"><div style='display:none;text-align:left;font:10pt times new roman;margin:0px 7%;' id='XBRLDIV'><ix:header><ix:hidden><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="From2022-03-30to2022-03-30">0000093314</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="From2022-03-30to2022-03-30" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type='simple' xlink:href='vnrx-20220330.xsd'></link:schemaRef></ix:references><ix:resources><xbrli:context id="From2022-03-30to2022-03-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000093314</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-30</xbrli:startDate><xbrli:endDate>2022-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="USDPShares"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>UNITED STATES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Washington, D.C. 20549</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:DocumentType">8-K</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>CURRENT REPORT</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>PURSUANT TO SECTION 13 OR 15(d) OF </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Date of Report (Date of earliest event reported): <strong><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen">March 30, 2022</ix:nonNumeric></strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:left;margin-left:auto;margin-right:auto;width:40%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-size:18pt"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityRegistrantName">VolitionRx Limited</ix:nonNumeric></span></strong></p></td></tr><tr style="height:15px"><td><p style="MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"><tbody><tr style="height:15px"><td style="width:30%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="margin:0px">&#160;</p></td><td style="width:30%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityFileNumber">001-36833</ix:nonNumeric></strong></p></td><td style="width:5%;"><p style="margin:0px">&#160;</p></td><td style="width:30%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><strong><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityTaxIdentificationNumber">91-1949078</ix:nonNumeric></strong></p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">(State or other jurisdiction </p></td><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">(Commission File Number)</p></td><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">(IRS Employer </p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">of Incorporation) </p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">Identification Number) </p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-family:times new roman,serif"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityAddressAddressLine1">13215 Bee Cave Parkway</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-family:times new roman,serif"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityAddressAddressLine2">Suite 125</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityAddressAddressLine3">Galleria Oaks B</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><span style="font-family:times new roman,serif"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityAddressCityOrTown">Austin</ix:nonNumeric>, <ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityAddressPostalZipCode">78738</ix:nonNumeric></span></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Address of principal executive offices and Zip Code)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160; </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>+1 (<ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:CityAreaCode">646</ix:nonNumeric>) <ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:LocalPhoneNumber">650-1351</ix:nonNumeric></strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Not applicable</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Former name or former address, if changed since last report.)</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160; Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160; Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric>&#160;&#160;&#160; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">Title of Each Class</p></td><td style="width:5%;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td><td style="width:5%;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">Name of Each Exchange on which Registered</p></td></tr><tr style="height:15px"><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;">Common Stock, par value $0.001 per share</p></td><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:TradingSymbol">VNRX</ix:nonNumeric></p></td><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="MARGIN: 0px; text-align:center;"><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen">NYSE American, LLC</ix:nonNumeric></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="color:#211d1e">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of </span><span style="color:#211d1e">the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><span style="color:#211d1e">Emerging growth company </span><ix:nonNumeric contextRef="From2022-03-30to2022-03-30" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="color:#211d1e">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span>&#9744;</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="font-size:1px;width:100%"><tbody><tr><td style="BORDER-BOTTOM: 2px solid;"></td></tr><tr><td style="BORDER-BOTTOM: 5px solid;"></td></tr></tbody></table><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="TEXT-INDENT: 0px;"></td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>VOLITIONRX LIMITED</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Form 8-K</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Current Report</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong>Item 2.02. Results of Operations and Financial Condition.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">The following information, including Exhibit 99.1, is being &#8220;furnished&#8221; in accordance with General Instruction B.2. of Form 8-K and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">On March 30, 2022, VolitionRx Limited (the &#8220;Company&#8221;) issued a press release announcing its financial results and certain business updates for its quarter and fiscal year ended December 31, 2021.&#160; The Company also confirmed its conference call to be held on March 31, 2022 at 8:00 a.m. U.S. Eastern Time.&#160; Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Item 9.01. Financial Statements and Exhibits.</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">(d) Exhibits.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:top;"><p style="margin:0px"><strong>Exhibit</strong></p><p style="margin:0px"><strong>Number</strong></p></td><td style="width:2%;"><p style="margin:0px"><strong>&#160;</strong></p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;"><p style="margin:0px"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px"><a href="vnrx_ex991.htm">99.1</a></p></td><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><a href="vnrx_ex991.htm">Press Release of VolitionRx Limited, dated March 30, 2022.</a></p></td></tr><tr style="height:15px"><td><p style="margin:0px">104</p></td><td><p style="margin:0px">&#160;</p></td><td>Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>SIGNATURE</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; TEXT-INDENT: 45px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px"><strong>VOLITIONRX LIMITED</strong></p></td><td></td></tr><tr style="height:15px"><td style="width:50%;"><p style="margin:0px">&#160;</p></td><td style="width:3%;"><p style="margin:0px">&#160;</p></td><td style="width:35%;"><p style="margin:0px">&#160;</p></td><td style="width:12%;"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">Date: March 30, 2022</p></td><td style="vertical-align:top;"><p style="margin:0px">By:&#160;&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;"><p style="margin:0px"><em>/s/ Cameron Reynolds</em></p></td><td></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">Cameron Reynolds</p></td><td><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">&#160;</p></td><td><p style="margin:0px">Chief Executive Officer &amp; President</p></td><td><p style="margin:0px">&#160;</p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr><tr style="height:15px"><td><p style='page-break-after: always'></p></td></tr><tr style="height:15px"><td>&#160;</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EXHIBIT INDEX</strong></p><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td style="BORDER-BOTTOM: #000000 1px solid;width:6%;vertical-align:top;"><p style="margin:0px"><strong>Exhibit</strong></p><p style="margin:0px"><strong>Number</strong></p></td><td style="width:2%;"><p style="margin:0px">&#160;</p></td><td style="BORDER-BOTTOM: #000000 1px solid;vertical-align:top;"><p style="margin:0px">&#160;</p><p style="margin:0px"><strong>Description</strong></p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="margin:0px"><a href="vnrx_ex991.htm">99.1</a></p></td><td><p style="margin:0px">&#160;</p></td><td style="vertical-align:top;"><p style="margin:0px"><a href="vnrx_ex991.htm">Press Release of VolitionRx Limited, dated March 30, 2022.</a></p></td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p><table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"><tbody><tr style="height:15px"><td class="hpbhr">&#160;</td></tr><tr style="height:15px"><td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr></tbody></table><p style="font-size:10pt;font-family:times new roman;margin:0px">&#160;</p></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>vnrx_ex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html><head><title>vnrx_ex991.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:right;"><strong>EXHIBIT 99.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>&nbsp;VolitionRx Limited Announces Full Fiscal Year 2021 Financial </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Results and Business Update</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Conference call to discuss financial and operational results scheduled for</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Thursday, March 31, at 8:00 am U.S. Eastern Time</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Executed global licensing and supply agreement with Heska Corporation to distribute Nu.Q<sup>&#174;</sup> Vet Cancer Screening Test at the Point of Care with a $10 million upfront payment and up to $18 million based upon the achievement of near/mid-term milestones.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Under said agreement will receive ongoing additional revenue for key components and kits.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">In advanced negotiations with other potential licensing partners in efforts to make Nu.Q<sup>&#174;</sup> Vet as accessible as possible worldwide.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Expanded its intellectual property portfolio.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Made significant progress with its Nu.Q<sup>&#174; </sup>NETs development.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Continued progress towards additional new product launches and licensing in both the human and veterinary spaces worldwide.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Approximately $20.6 million in cash and cash equivalents on the balance sheet as of December 31, 2021.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>AUSTIN, Texas, March 30, 2022 /PRNewswire/</strong> -- VolitionRx Limited (NYSE AMERICAN: VNRX) (&#8220;Volition&#8221;) today announced financial results and a business update for the full fiscal year ended December 31, 2021. Volition management will host a conference call tomorrow, March 31 at 8:00 a.m. U.S. Eastern Time to discuss these results. Conference call details may be found below.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&#8220;I could not be prouder of the team&#8217;s achievement in securing a global licensing and supply agreement for our Nu.Q<sup>&#174;</sup> Vet Cancer Screening Test with Heska Corporation, one of the industry&#8217;s leading companies,&#8221; commented Cameron Reynolds, President and Group Chief Executive Officer of Volition. &#8220;Volition Veterinary is an exciting, fast-moving part of our business with clear potential to generate significant revenue for the company, initially under our agreements with Heska and SAGE Healthcare, through both milestone payments and ongoing sales of kits and key components. We have also made good progress in other key areas including our Nu.Q<sup>&#174;</sup> NETs and Nu.Q<sup>&#174;</sup> Capture programs as we shift gears towards our goal of becoming a commercial company with products.&#8221;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>An interview with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Terig Hughes, Group Chief Financial Officer of Volition.</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><u>https://youtu.be/QH2pMGufmWg</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Company Highlights</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Financial</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Cash and cash equivalents as of December 31, 2021, totaled approximately $20.6 million compared with $19.4 million as of December 31, 2020.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Subsequent to year end, Volition is due to receive a $10 million upfront payment as a result of the execution of the agreement with Heska Corporation.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Cash burn rate averaged approximately $2 million per month.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Net loss for the full year of 2021 was $27 million versus $20.4 million for 2020 with this increase primarily due to non-cash items in addition to new hire staffing costs.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Signed our first Nu.Q<sup>&#174;</sup> Discover agreement in 2021 and subsequent to year end have signed an additional five agreements worth an aggregate of approximately $200,000 on a full-year basis.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Made strong progress in improving internal controls and processes and anticipate the remaining weakness regarding segregation of duties in finance will be resolved in 2022.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Commercial Opportunity</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">We estimate our annual total addressable market (&#8220;TAM&#8221;) to be approximately $70 billion worldwide including Nu.Q<sup>&#174;</sup> Vet, Nu.Q<sup>&#174;</sup> Discover, Nu.Q<sup>&#174;</sup> NETs and Nu.Q<sup>&#174;</sup> Cancer.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">All estimates are global and on an annualized basis using key assumptions as follows:</td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">We estimate the Nu.Q<sup>&#174;</sup> Vet TAM to be approximately $11 billion based on global canine and feline populations that are eligible for screening and monitoring and a price assumption of $50 per test to the consumer.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">For Nu.Q<sup>&#174;</sup> Discover we estimate the TAM to be over $200 million using drug pipeline data of registered clinical trial programs for relevant epigenetic targets.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">We estimate the Nu.Q<sup>&#174;</sup> NETs TAM to be approximately $22 billion calculated using estimated hospital admissions and discharges for sepsis and the associated average length of stay.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">We estimate our Nu.Q<sup>&#174;</sup> Cancer TAM to be approximately $37 billion calculated based on eligible populations for annual screening, target participation rates and incidence/prevalence of specific cancers, and risk stratification use cases.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">Price per test assumptions for Nu.Q<sup>&#174;</sup> and Nu.Q<sup>&#174;</sup> NETs range from $120 for the U.S., $50 for Europe and $25 for the rest of the world.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Personnel/ Operational</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">To support our commercial expansion, we welcomed Terig Hughes as our Chief Financial Officer, Gael Forterre as our Chief Commercial Officer, Dr. Tom Butera as the Chief Executive Officer of our veterinary subsidiary, and Mr. Nick Plummer as Group General Counsel.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">In addition, Gaetan Michel was promoted to Chief Operating Officer and has relocated to the U.S. to accelerate the development of Volition America.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Dr. Terry Kelly was promoted to Chief Innovation Officer and is building a team focused on cutting-edge, discovery research at our new innovation hub which opened in California in March 2022.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Volition Veterinary</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Executed a global licensing and supply agreement with one of the industry&#8217;s leading companies, Heska Corporation.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">In exchange for granting Heska exclusive worldwide rights to sell the Nu.Q<sup>&#174; </sup>Vet Cancer Screening Test for companion animals at the Point of Care, Volition will receive:</td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">a $10 million upfront payment on signing,</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">up to $18 million based upon the achievement of near/mid-term milestones, and</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">ongoing additional revenue for key components.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">In addition, Volition has granted Heska non-exclusive rights to sell the Nu.Q<sup>&#174;</sup> Vet Cancer Screening Test in kit format for companion animals, through Heska&#8217;s network of central reference laboratories for which Volition will receive ongoing additional revenue for such kit sales.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Appointed SAGE Healthcare as a non-exclusive licensee and distributor of our Nu.Q<sup>&#174;</sup> Vet Cancer Screening Test for the Asian market.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">We remain in advanced negotiations with other potential licensing partners in our efforts to make Nu.Q<sup>&#174;</sup> Vet as accessible as possible worldwide and anticipate further announcements in 2022.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Published two peer-reviewed clinical papers and two abstracts at the Veterinary Cancer Society Annual Conference including the first data demonstrating the use of Nu.Q<sup>&#174;</sup> Vet as a disease monitoring tool.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Clinical &#8211; NETosis including COVID-19</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Volition believes the Nu.Q<sup>&#174;</sup> NETs assay will have wide applicability for monitoring diseases with a NETs component (such as COVID-19, influenza, sepsis, autoimmune diseases, and cancer) and potentially to risk-stratify patients for treatment selection.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Volition expects to register CE marks on its first NETs product, across multiple platforms including ELISA plate, automated beads, and a proof of concept on a very high throughput platform by the summer of 2022.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Volition intends to register the Nu.Q<sup>&#174;</sup> NETs product with a broad almost C-reactive protein (CRP) style claim &#8220;for the detection and evaluation of infection, tissue injury, inflammatory disorders and diseases associated with NETosis.&#8221;</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Posters published during 2021 (at the International Society on Thrombosis and Haemostasis Congress) showed that results on admission using the same Nu.Q<sup>&#174;</sup> NETs assay could predict future COVID-19 disease severity and that serial results correlate with disease progression including 28-day mortality.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Further larger studies have been completed in COVID-19 and sepsis which are now awaiting publication, as well as studies in other diseases in progress, with results expected in the coming quarters.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Clinical &#8211; Cancer</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Published data at ASCO GI 2022 for two colorectal cancer studies (asymptomatic and symptomatic populations) conducted with the National Taiwan University.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Results demonstrated that using Nu.Q<sup>&#174;</sup> assays in conjunction with FIT could potentially reduce unnecessary colonoscopies by up to 28% in patients with gastrointestinal symptoms and that this dual approach could also improve the effectiveness of FIT-based screening programs for asymptomatic patients.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The Lung Cancer team at the National Taiwan University has completed collection and preliminary analysis and submitted abstracts to upcoming conferences.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Volition has also undertaken active and continuing negotiations in Asia, in addition to platform development on its first human cancer launch in China.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Collection for the U.S. Early Detection Research Network (&#8220;EDRN&#8221;) study restarted in June 2021 and enrollment has been slow but steady. The EDRN has diverted some efforts to drive recruitment and it still anticipates study completion in the fourth quarter of 2022.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">With regards to Volition&#8217;s U.S. blood cancer studies, the timing of expected completion for each has been impacted by the COVID-19 pandemic due to sample collection and protocol issues.</td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">Given the pandemic, and resultant delays in the larger Non-Hodgkin Lymphoma (&#8220;NHL&#8221;) study (of 1500 subjects), the Company has taken the opportunity to upgrade the platform to a high-throughput platform which will help facilitate an FDA compliant product. Consequently, Volition now expects this study to initiate recruitment in the second quarter of 2022 with study completion anticipated in 2023.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">A smaller, proof of concept NHL monitoring study is ongoing. However, due to missing serial samples as a result of pandemic collection issues, we are not in a position to publish yet. Collection continues and we anticipate analyzing a more complete data set in 2022.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Nu.Q<sup>&#174;</sup> Capture</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">The Nu.Q<sup>&#174;</sup> Capture program now has several strands of technology which:</td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">essentially remove background noise, thereby amplifying the signal,</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">look to identify the signal in a novel way including through mass spectrometry, or</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">isolate various chromatin fragments, including nucleosomes and transcription factors.</td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Nu.Q<sup>&#174;</sup> Capture, when used in combination with either sequencing, mass spectrometry and/or Volition&#8217;s Nu.Q<sup>&#174;</sup> assays could potentially aid diagnosis, treatment selection, and both treatment and disease monitoring in addition to aiding biomarker discovery.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Further to the publication in 2021 of a novel method utilizing Nu.Q<sup>&#174;</sup> Capture and mass spectrometry, Volition is developing a large 1000-plus patient study in lung cancer and colorectal cancer with further announcements expected in 2022.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Intellectual Property</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">29 patent families (plus three in-licensed families) covering both human and animal use of Volition&#8217;s Nucleosomics&#8482; platform.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">84 granted patents (12 in the U.S., 14 in Europe, and 58 rest of world).</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">93 patents pending worldwide.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Continued focus on filings and expect portfolio to grow in the quarters and years ahead.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Publications</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">In 2021, data for the Nu.Q<sup>&#174;</sup> platform was presented at five international conferences and Volition has collaborated on four clinical papers.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">In 2022, to date, two posters were presented at the ASCO GI 2022 conference.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">These publications are another very important step forward for the Company.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong><em><u>Upcoming Milestones</u></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Drive near term revenue in the following key areas:</td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:8%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">Licensing of its technology, with a particular but not exclusive focus on Nu.Q<sup>&#174;</sup> Vet.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">Complete Heska Corporation agreement milestones in order to receive further milestone payments.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">Sales of key components of Point of Care test with Heska.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">Sales of kits from non-exclusive agreements for the use of Nu.Q<sup>&#174;</sup> Vet via central reference labs.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">Ongoing and new Nu.Q<sup>&#174;</sup> Discover agreements.</td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="margin:0px">o </p></td> <td style="vertical-align:top;">Sales of its disease monitoring tests (e.g. COVID-19, sepsis).</td></tr></table> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Continue to progress the research program for the use of Nu.Q<sup>&#174;</sup> in NETosis, in monitoring disease progression of COVID-19, sepsis, and potentially other diseases and as a possible companion diagnostic for a treatment for sepsis.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Continue to advance its previously announced large-scale blood, lung, and colorectal cancer trials in Europe, Asia, and the U.S.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Publish several abstracts and peer-reviewed scientific papers with clinical results showing the robustness and utility of its Nu.Q<sup>&#174;</sup> platform.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Advance the development of Nu.Q<sup>&#174;</sup> Capture.</td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;">Continue to file patents to expand and extend its intellectual property portfolio.</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>VolitionRx Limited Full Fiscal 2021</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:center;"><strong>Financial Results and Business Update</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><strong>Date: </strong>Thursday, March 31, 2022</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><strong>Time: </strong>8:00 a.m. U.S. Eastern time</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><strong>U.S. &amp; Canada Dial-in: </strong>1-877-407-9716 (toll free)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><strong>U.K. Dial-in: </strong>0 800 756 3429 (toll free)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><strong>Toll/International: </strong>1-201-493-6779</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 45px; text-align:justify;"><strong>Conference ID: 13728406</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Cameron Reynolds, President and Group Chief Executive Officer of Volition, will host the call along with Terig Hughes, Group Chief Financial Officer of Volition, Dr. Tom Butera, Chief Executive Officer of Volition Veterinary Diagnostics Development LLC, and Scott Powell, Executive Vice President, Investor Relations of Volition. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">A live audio webcast of the conference call will also be available on the investor relations page of Volition's corporate website at <u>http://ir.volition.com</u>. In addition, a telephone replay of the call will be available until April 14, 2022. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13728406.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>About Volition</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Volition is a multi-national epigenetics company that applies its Nucleosomics&#8482; platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics&#8482;, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Volition's research and development activities are centered in Belgium, with an innovation laboratory in California and additional offices in Texas, London, and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">For more information about Volition, visit Volition's website <u>volition.com</u> or connect with us via:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Twitter: <u>https://twitter.com/volitionrx</u> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">LinkedIn: <u>https://www.linkedin.com/company/volitionrx</u> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Facebook: <u>https://www.facebook.com/VolitionRx/</u> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">YouTube: <u>https://www.youtube.com/user/VolitionRx</u></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Media Enquiries:</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Louise Batchelor/Debra Daglish, Volition, <u>mediarelations@volition.com</u> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">+44 (0)7557 774620</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>Safe Harbor Statement</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Statements in this press release may be &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;targets,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;optimizing,&#8221; &#8220;potential,&#8221; &#8220;goal,&#8221; &#8220;suggests,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;may,&#8221; &#8220;will&#8221; and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition&#8217;s expectations related to the potential benefits under the agreements with Heska and SAGE, the size of Volition&#8217;s addressable markets, the success of negotiations and the timing, completion and execution of term sheets and/or agreements with third parties regarding the licensing and distribution of Volition&#8217;s products, the timing, completion and delivery of data from clinical studies, effectiveness of Volition&#8217;s blood-based diagnostic, prognostic and disease monitoring tests, Volition&#8217;s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, the timing of product launches and publications, and expectations regarding Volition&#8217;s ability to transition to a commercial products company, its future revenue and financial performance. Volition&#8217;s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition&#8217;s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition&#8217;s development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition&#8217;s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition&#8217;s intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring markets and their rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition&#8217;s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition&#8217;s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="font-size:10pt;font-family:times new roman;margin:0px 0px 0px 0in">Pursuant to the disclosure requirements of the NYSE American Company Guide Section 610(b), Volition is reporting that its audited consolidated financial statements for the fiscal year ended December 31, 2021, included in Volition&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 30, 2021, contains an audit opinion from its independent registered public accounting firm that includes an explanatory paragraph related to Volition&#8217;s ability to continue as a going concern. This announcement does not represent any change or amendment to Volition&#8217;s financial statements or to its Annual Report on Form 10-K for the fiscal year ended December 31, 2021.&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;">Nucleosomics&#8482; and Nu.Q<sup>&#174;</sup> and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to &#8220;$&#8221; refer to the legal currency of the United States of America.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>vnrx-20220330.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/30/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<schema xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:vnrx="http://vnrx.com/20220330" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vnrx.com/20220330">
 <annotation>
  <appinfo>
   <link:roleType roleURI="http://vnrx.com/role/Cover" id="Cover">
    <link:definition>000001 - Document - Cover</link:definition>
    <link:usedOn>link:presentationLink</link:usedOn>
    <link:usedOn>link:calculationLink</link:usedOn>
    <link:usedOn>link:definitionLink</link:usedOn>
   </link:roleType>
   <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20220330_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20220330_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20220330_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
   <link:linkbaseRef xlink:type="simple" xlink:href="vnrx-20220330_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
  </appinfo>
 </annotation>
 <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
 <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
 <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
 <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
 <import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd" />
 <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd" />
 <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
 <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
 <import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd" />
 <import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd" />
 <import namespace="http://fasb.org/srt-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd" />
 <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
 <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
 <import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
 <import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
 <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
 <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
 <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>vnrx-20220330_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/30/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address Address Line 1</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address Address Line 2</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address Address Line 3</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address City Or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address State Or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>5
<FILENAME>vnrx-20220330_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/30/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20220330.xsd#Cover" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Document and Entity Information" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>vnrx-20220330_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/30/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20220330.xsd#Cover" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
    <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>vnrx-20220330_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--XBRL Document Created with XBRLMaster-->
<!--Version: 2.3.08-->
<!--Based on XBRL 2.1-->
<!--Date of creation: 03/30/2022-->
<!--Software architectural design and coding: A'c Dharmapremananda Avt.-->
<!--Copyright (c) 2022 I-NET Business Solutions, Inc. All Rights Reserved.-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef  roleURI="http://vnrx.com/role/Cover" xlink:href="vnrx-20220330.xsd#Cover" xlink:type="simple" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:definitionLink xlink:type="extended" xlink:role="http://vnrx.com/role/Cover" xlink:title="00000001 - Document - Cover Page Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCover" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140511046053000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Mar. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VolitionRx Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000093314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 30,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">91-1949078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address Address Line 1</a></td>
<td class="text">13215 Bee Cave Parkway<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address Address Line 2</a></td>
<td class="text">Suite 125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address Address Line 3</a></td>
<td class="text">Galleria Oaks B<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address City Or Town</a></td>
<td class="text">Austin<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address Postal Zip Code</a></td>
<td class="text">78738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">650-1351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VNRX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>vnrx_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vnrx-20220330.xsd" xlink:type="simple"/>
    <context id="From2022-03-30to2022-03-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000093314</identifier>
        </entity>
        <period>
            <startDate>2022-03-30</startDate>
            <endDate>2022-03-30</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-03-30to2022-03-30">0000093314</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-03-30to2022-03-30">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-03-30to2022-03-30">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-03-30to2022-03-30">2022-03-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-03-30to2022-03-30">VolitionRx Limited</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-03-30to2022-03-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-03-30to2022-03-30">001-36833</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-03-30to2022-03-30">91-1949078</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-03-30to2022-03-30">13215 Bee Cave Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-03-30to2022-03-30">Suite 125</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="From2022-03-30to2022-03-30">Galleria Oaks B</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="From2022-03-30to2022-03-30">Austin</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-03-30to2022-03-30">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-03-30to2022-03-30">78738</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-03-30to2022-03-30">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-03-30to2022-03-30">650-1351</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-03-30to2022-03-30">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-03-30to2022-03-30">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-03-30to2022-03-30">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-03-30to2022-03-30">false</dei:PreCommencementIssuerTenderOffer>
    <dei:TradingSymbol contextRef="From2022-03-30to2022-03-30">VNRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-03-30to2022-03-30">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-03-30to2022-03-30">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<?/;M>"0)%T%>+_4VIX*[IQ;_$TQ_ =02P,$%     @ O8%^5)^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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MH'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]02P,$%     @
MO8%^5"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_O
MR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!
MV#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6
MHJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0
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M&G_FB^$_7G\!4$L! A0#%     @ O8%^5 =!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " "]@7Y4]SIV
M$>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " "]@7Y4F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( +V!?E1=(J\?(@0  +(0
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " "]@7Y4GZ ;\+$"  #B#   #0              @ %E#
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( +V!?E27BKL<P    !,"   +
M          "  4$/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( +V!?E2JQ"(6
M,P$  "("   /              "  2H0  !X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    " "]@7Y4)!Z;HJT   #X 0  &@              @ &*$0  >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "]@7Y499!YDAD!
M  #/ P  $P              @ %O$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08     "0 ) #X"  "Y$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="vnrx_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vnrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="vnrx_8k.htm">vnrx_8k.htm</File>
    <File>vnrx-20220330.xsd</File>
    <File>vnrx-20220330_cal.xml</File>
    <File>vnrx-20220330_def.xml</File>
    <File>vnrx-20220330_lab.xml</File>
    <File>vnrx-20220330_pre.xml</File>
    <File>vnrx_ex991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vnrx_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "vnrx-20220330_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vnrx-20220330_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vnrx_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vnrx-20220330_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vnrx-20220330_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vnrx-20220330.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 24,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "vnrx",
   "nsuri": "http://vnrx.com/20220330",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_8k.htm",
      "contextRef": "From2022-03-30to2022-03-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000001 - Document - Cover",
     "role": "http://vnrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "strong",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vnrx_8k.htm",
      "contextRef": "From2022-03-30to2022-03-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line 1"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line 2"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address Address Line 3"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://vnrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001477932-22-001739-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001477932-22-001739-xbrl.zip
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M)Y(3+@"3\Y4"^?L7O'H,NW>O//;D=V6O_=Z%$.=T,WJU'[=_ %!+ P04
M" "]@7Y4^BXUX98"  !("   %0   '9N<G@M,C R,C S,S!?9&5F+GAM;+U5
M46_:,!!^G[3_<,L>MDESG)!56E%I!70/E>@TT6WJ6V6<@UAS;&8[0/_][(1D
MH%*I3&(\H,3W??=]=W9\%U>;4L(*C15:#:(T3B) Q74NU&(0598PRX6(P#JF
M<B:UPD'TB#:ZNGS]ZN(-(?>CZ02N-:]*5 [&!IG#'-;"%1!"M\PZ-(1LT3\;
MG3[TXBQ./G?K(V8]2ZN:XX-I%[GV^4#/@8?,-37):);07M+K=: [/7=K9A"8
MX85PR%UEF(0<K5@H\,:A*:@/PW<<K@MF2K8T6#(5BH+ARL5=KK%>/AJQ*!R\
MYQ\@R, -^?KE.XPJ*Q1:"W=:5L&*_0@WBL<PE!*F@6%ABA;-"O-M.BG4KW[X
MF_GZP#=:V?[&BD%4.+?L4[I>K^-U%FNS\/4D*;V_G=SQPOLB0H6&<XQ:5LAR
MB)>>GY_3.MI"GR W,R-;C8RV=KK,/IJ[CK +/J--T$.MZ-O:V43S>A]>H #/
M(L(;:6$D+)&T1[(TWM@\\HT#:%IGM,0IS@'"PX_I32>Z4F83<UW2$*!C[<^O
M-UES"H/S010 )&Q>DF5)2/MV#^0>E_X<6U$NI6\$W9'T)ZA5/03=U7BFO+9K
MH:ZS6KKP*0RO9DARX3^3\ 5$L!7:K:K+(I2C'DJW&'HPP:E==U(DUR431UI^
MRCZYWUJ'E%C.PD8?97:?>FJG3,KC_-6$4[M2V@V/-=9R_N-9Q#FKI/OGP]C2
M=QW[1:%$N-4F_G7/-6X<JASSUG=(]Y);R D7@$GS2X'\G9$$:B1\8POT V2N
M_3 *VLW%UWJ2FN\9D>'>U>9I_VQ;N$4>+_2*YBC"=$Q_?PJ/I'ELNHCBH=8>
MSJPSC+LVFV0SE+7&@\=L"]EVB!YH49AM=&^X7?X!4$L#!!0    ( +V!?E0J
MK>49' 8  #LZ   5    =FYR>"TR,#(R,#,S,%]L86(N>&ULS9MKC^(V%(:_
M5^I_.*4?VDH-&:"J.FAG5RP[6Z'.3<-LNVI5K4)BP-K$9FTSP+^OG0M#$CLP
MHZWC+S,0O\=^C\\CQ[GPZLTVB>$1,8XIN>CTNF<=0"2D$2:+B\Z:>P$/,>X
M%P&)@I@2=-'9(=YY\_K;;UY]YWD?W]Y?P3L:KA-$!(P9"@2*8(/%$E33=< %
M8IZ7J__,QAE"OSOHGOVV/_XVX#**DC1&-O;V+>]D?T#G$*J>T]"S@3\X\_MG
M_?Y>-*5SL0D8@H"%2RQ0*-8LB"%"'"\(2..0)32$T0\AO%L&+ E6#"4!44G!
MZ%%T]WV-Z6K'\&(IX,?P)U##P,2[N7R MVN.">(<IC1>*RO\9YB0L NC.(9[
M%<'A'G'$'E&4=Q=C\GFH_LQD?B GFO#AEN.+SE*(U=#W-YM-=S/H4K:0^9SU
M_(_75]-P*7UYF*@)#U&GB%*]Z.)ZY^?G?MI:2&O*[8S%Q1@#O[ CY1P/>3K<
M%0W3R3TA#(P*]<TK9)XZY/7ZWJ#7W?*H(V<#()L/1F-TC^:0FAZ*W4H2Q7&R
MBI6E]-B2H;G>2LR8K^)]@A8*-#7,N1JF]ZL:YOO\\%4P0W$'E/+#_<28U7FI
MKSS(/]'J\SJ_0PS3Z)(4HWRE1*O=GFK^JPX_%0$3+YKR>KSE!!ZH".(763^,
MM&SZ!KULMI_B;,^R7/71RV;Y(/)_,"WJAI\]M;HYC=6A*_FI9!!M!2(1B@J+
MJH.&%3?M/UW8TY[W?=.PU&NLUF[*ZGESV6O:(T=A=T$?_0AA==KL??E%??2R
MCVG:\NNG,96;@-&,"Q:$HN@M3>2BHVGWRZ:4;L0*9_(T?"2Y7.&'5)[D5L*+
M#Y?%.:.)=M \;ZII_!3/]O'9Q,@AM#9+(H8X7;,0/:LFAUY-,Y3[26*I4#LI
M1+P/T\[K5 /_%*I_7_E/O5@I\R416.SNT0(K!T3<! G2Y**7V2EZD\6B]CJ-
M P@TV*J2D$GA20M*W!(/8[EYESOFB5R>MG^@G3&SFLXF$0:3920J(F>8T/LR
M0)&+(56#E%O'HKBB>Y"]:G(J-]N!0&>IJ/UAFP,EU]BI5GI_R:PTULL[DD-'
M:OCW<;#0)%!IMU-@K:FBPJ5&!TJL\U.M\5X#2M32TGZ9(+; 9/$[HQNQ'--D
M%1#S F]0VUSF&PV7%WNMU $XCKLS+/Q%"&0QD >UMOSO[R^HVW -"UU%9_>$
MH#59/3.41 X@TN3+>*[(Q"#5H.0MK2@3$E*VHBR]93@5TLB8KN6&93>FD?E:
MXDB4S17FI 3**TUCB ,XG>[2L/*40B&-A3P85'1+K#T$VTDDT<=SG-VBOEDG
M,\2,,V#4V^3KB.DR60:Q,TPU^S/0)(.@' 59F'6,_F)8"$3DB319D]P+UR1K
MT-G!IM%D@8M6Y  F3;ZJ>.1:*(NM0S&E,0ZQD!NM:[G.,1SH\M*)[.!@ME>P
M4%<X (+15)6")R$42NL(W#&D($2R$.F5NKHSSV[G<^VYI4EL!XGC=@LTS$H'
M$#EJKHJ*#(##",A"((UI&YH)YVO$GH6.)J05@(S6#1C5].[!9+)X%*DLL%VR
MLGW3>QRC(QO<0XG-/6W=6GD;^]3N !D&2X;-JM*UM3W-+(RB2*;/\W]7F*">
M,2NMUB8)#6;+2&B$SK!A]F: )%?N_ZL0Z#G#2_\9F?;;YJ5_*B]]AWGIOX"7
MOC.\#)Z1Z:!M7@:G\C)PF)?!"W@9M,O+6'Z\90]T0X[E>:AL@96Z42TI3S+7
M.*DY.T*)TL.MW+/*B'892>\4W[([1A\Q"<VW_TWR%F@Q6-8B4]&ZQHW>WA%X
MLIO[DIXBK%V"[B@70?PW7C4^/M*+6Z!':U?+3DGI&CDZ<T>XR4) QK3S1$@M
M>B.& @,GY69+[Z=J+.U?3SUH<Z#Z&CNUEU/3:DM-._55OT*)[Y:4F.^!U"5V
MZFRR5M2ZVNY O0V6JC5/99#JVKH'\L "]>.LZ2Z945TFE78[%=>:*LI=:G2@
MUCH_U4+G&LA$]A^YH7#-U$M1VW I;2'#>^=ZF:7';@T6]P_>-!H' &BP57OX
MEDNAT.K?.S\\(*]%/ZN?,^:'</83O]?_ 5!+ P04    " "]@7Y4;DCIJY$$
M  #O)   %0   '9N<G@M,C R,C S,S!?<')E+GAM;,V:6X_B-A3'WROU.[CT
MH:W4$"#;=@?-[(IA9BO4N2"@[:HO*Y,<P%K'9FUS^_8]#I<=( F>EWAYX):_
M[?/_'<?Q(5R_7Z><+$%I)L5-K5EOU B(6"9,3&]J"QU0'3-6(]I0D5 N!=S4
M-J!K[]]]_]WU#T'P\7;P0.YDO$A!&-)50 TD9,7,C-A#CU0;4$&P4_^S':=-
M6O6HWGA[^/Z6:FPE1=8&#S8/1^ZP/R(G)+8]9TT;41@UPE:CU3J(AG)B5E0!
MH2J>,0.Q62C*20*:307!P,G64)MT?HK)W8RJE,X5I%184Z2S-/5#7UTYWR@V
MG1GR<_P+L<.07O!T/R*W"\T$:$V&DB]L*/I7TA-QG70X)P/;0I,!:%!+2';=
M<28^M^W3&/T1!"UT>ZW936UFS+P=AJO5JKZ*ZE)-T4^C&7Y\?!C&,XPK8,("
MCZ&V;V5[R6O7O+JZ"K.C>^F9<CU6?#]&%.[#0;EF;9T-]R#C#*Y#,U*HL)^"
MO2RP7P7-5A UZVN=U) &(5L>2G(8P(38U[\'O<.82Z'6]5BFH3T0=B7.28PQ
M:S)3,+FI64%@$]*(HH;M]<<CD=G,<6YJELXYF@M?C(BIUC@[,XL/^,51 U@;
M$ DD^V[LZ"XQ&6:LL+%]-$GP]2P(2*8D?3H%G"(3B=/-CKVEL(^*R_@H$&Z3
M($\\VS@T!I*AUA#7IW(9)L#L_&]^>6/?!MNW&1#\^"D;NS/61M'8['OC= P\
M&^,3:DXD825QW0M$MAG E-EQA7FB*>2'EZ\\CO)E3CLJ)E(EH# =^QYQ)3C*
MY/E\W2G".2X<P@2X</##))@HF1;1VK&1%\)]B1"'JI9R%QWA"MC#B;W^"S9E
MF,^D3IR;WC@76*L<]/YL'V&O^7R/%4Y86QZPYAFIG&8'(TAL%!\XG>;C/)$X
M\8P\\,RUXFD=N$]!37'C\Z>2*S/KRG1.1>EJ4-# "?8;;VM"J4UO*T,?%)/)
MO4CL'K9\B3B1.N'^S>-:D6O-TQS'/;A4<ZDR/D/$!%VYP&O$IBN3T@W&A89.
M2?C=VYQWLNTI)2.Z[B5HDDW8MK!X6J3CKUOGO&04-G%*PQ_>TG#!:N4)^%<Q
M@P4-KH'I0NQ"TOG@"Z1.P-]Z %YJK7+00\E9S Q>=1[QW%.,\GS*>3HGQ%<>
M$!>;JIQO7X'--(@8LMVI+=+5\V12M(R4Z=U*&A^UXV67OL'WM%Z >BW^G%9N
M2?!16+HZ]G0U_< X7+Z OE2YH?91;!8Y\H2VDR0(1^]>'IB 9AGC7+D;;!^5
MZ$6/WPSUUNNHMURI^RM)2SQ^,]2CUU&/7*G[J$PO>O1+O8MOG]5(KH0#\Y=B
M-^+^RM!"?WYY9P7QL^HKN63;VVB7H)^U<"/OK_(L=^H7?U]J0_E_;'[I-YA\
MO1MZ'S7H99>5@[>G7D<!+49]K'"#ZZ/ZS'-2.4Y[+YSW9U*4[KG/56[W=WS4
MF$6.*D<[4M3^"V.X2<>RX->2$XD;5!\U8ZZ7ZG^$@GBA[ V0=3RC8@K%]]3S
ME6Y\?12*9<[.,%^'9_'CWN^S_0O.]HA]LG]+>?<_4$L#!!0    ( +V!?E3
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MY',<JU($W#8B?R /(GA6?73@(>9X5!*7];@?=P+$&8AU@ <[+;"]P,B"# 4
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M7F\3;\+>?2P AX63.IW9H0P)1*+TI1)PQ SM):!HI!V7JJ@54@QQH:8B,3F
M"MYD GRAJ[6$Q7$!B[Q$]$IACT>FTH29CO'( "9849H*UJEGL+R4MBJ4=4(7
M0@T!*  '0*A<7ER%QQ* E0!?=1II"OPJC?][8FR6P@E7ZPC$HT\EX ! $)
M %(!=5-)50/ 2HO\IYK"0FTU!$G#K./ZWLD4. #\UD.XAY3$&C@XSF,)KGIN
MSP5O^LG1N1,IG)S,E'C*UG'Q(&E4&DY^VJRZ,A-I4]<F#\CGX'Y:)Y7() B/
M8\6$H3DR<%(&<*"(NHYK8(ET_U(!106)Q8(6 5P5WEKKH[!? A0^Z1R$4&"
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M+XQA$]81D@<-0K6C,<61M$ Z#J,V<1H";TZ\/3ZDS1P=GI[$O!FD\A2D4Z'
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M-Q?M=&L(,I]7$=W\K8QV1+"9+'B7:/+74CP\Y<'[YI1>-P_)1)AZ%GS4U@Q
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M)S],M*^O",/WF<.^-*NO6'O;=O8556.T*.YP_67R3\\PM(ZXU"#9M*6>(.N
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M4$L! A0#%     @ O8%^5"JMY1D<!@  .SH  !4              ( !G D
M '9N<G@M,C R,C S,S!?;&%B+GAM;%!+ 0(4 Q0    ( +V!?E1N2.FKD00
M .\D   5              "  >L/  !V;G)X+3(P,C(P,S,P7W!R92YX;6Q0
M2P$"% ,4    " "]@7Y4P+[W>X(/  !X6@  "P              @ &O%
M=FYR>%\X:RYH=&U02P$"% ,4    " "]@7Y4#?=VCD B  ![O@  #@
M        @ %:)   =FYR>%]E>#DY,2YH=&U02P4&      < !P#  0  QD8
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
